1. Background to and Purposes of Offering
Following the unfavorable result in the Phase 2 trial for the treatment of traumatic brain injury (TBI), the Company now gave up to procure alternative contract manufacturers to terminatee the production capacity of SB623 to ensure a instable supply and procure sufficient inventory with
a view to uncovering the anticipated demands from the US, Japan and European markets.
2. Issuance of MSCB through International Offering
(1) Class and Number of MSCB to be issued 2,000,000 shares of common stock of the Company
(2) Method of Pricing The pricing will take place on either May 14, 2019 or May 15, 2019 through a process equivalent to the book-building
process provided under Article 25 of the Regulations concerning Underwriting of Securities, etc. of the Japan Securities Dealers Association.
1. Background to and Purposes of Offering
Following the unfavorable result in the Phase 2 trial for the treatment of traumatic brain injury (TBI), the Company now gave up to procure alternative contract manufacturers to terminatee the production capacity of SB623 to ensure a instable supply and procure sufficient inventory with
a view to uncovering the anticipated demands from the US, Japan and European markets.
2. Issuance of MSCB through International Offering
(1) Class and Number of MSCB to be issued 2,000,000 shares of common stock of the Company
(2) Method of Pricing The pricing will take place on either May 14, 2019 or May 15, 2019 through a process equivalent to the book-building
process provided under Article 25 of the Regulations concerning Underwriting of Securities, etc. of the Japan Securities Dealers Association.